Female Pelvic Floor Dysfunction Clinical Trial
— PFD POP UIOfficial title:
The Study of Susceptibility Genes Localization for Female Pelvic Floor Dysfunction
| Verified date | June 2014 |
| Source | Third Military Medical University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | China: Ethics Committee |
| Study type | Observational |
Female pelvic floor dysfunction (FPD) is due to defects in the pelvic support structures,
degradation, damage or dysfunction. The main problem of which is pelvic organ prolapse(POP),
urinary incontinence(UI) and genital tract injury. Although it does not pose a serious
threat to life, but affect the patient's quality of life seriously in the physical,
psychological, social behavior and other aspects. With the growing aging population, the
incidence rate has gradually increased, and increasing demands for people's quality of life
simultaneously, more and more attention was raised to PFD as common chronic diseases.
In recent years, the basic research, epidemiology, prevention, diagnosis and treatment of
PFD have made great progress, especially in developing gynecological urology theory and
reconstructive pelvic surgery. But overall the basic research of PFD is lagging behind,
especially susceptibility gene localization and functional studies did not get enough
attention.
| Status | Enrolling by invitation |
| Enrollment | 200 |
| Est. completion date | October 2017 |
| Est. primary completion date | October 2016 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 30 Years to 70 Years |
| Eligibility |
Inclusion Criteria: 1. female aging from 30 to 70-year old; 2. preoperative diagnosis of gynecologic malignancies; 3. have the ability to comply with Research programs; 4. voluntarily participate in the study and signed an informed consent form Exclusion Criteria: 1. patients with severe cardiovascular diseases, kidney, liver and other vital organs diseases, bone marrow disease and mental illness; 2. patients suffering from autoimmune diseases; 3. patients with acute infectious disease or infection early phase of infection; 4. patients with urinary tract infection; 5. patients with infection or erosion of ano-genital skin; 6. for any other reason, the researchers considered unsuitable for inclusion. |
Observational Model: Case Control, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| China | Department of Obstetrics and Gynaecology, Southwest Hospital, Third Military | Chongqing | Chongqing |
| Lead Sponsor | Collaborator |
|---|---|
| Zhiqing, Liang | Shenzhen Huada Genomics Co., Ltd. |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | susceptibility genes localization | Based on high-throughput sequencing platform, we expect to screen out susceptibility genes location in PFD, providing theoretical basis for individualized prevention, intervention and treatment. | 4 years | No |